Treatment with the immunomodulator AM3 improves the health-related quality of life of patients with COPD.

[1]  V. Brusasco,et al.  Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. , 2003, Thorax.

[2]  A. Agustí.  Systemic effects of chronic obstructive pulmonary disease. , 2005, Proceedings of the American Thoracic Society.

[3]  S. Spencer,et al.  Impact of preventing exacerbations on deterioration of health status in COPD , 2004, European Respiratory Journal.

[4]  A. Pont,et al.  Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study , 2004, Thorax.

[5]  I. Adcock,et al.  Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase , 2004, The Lancet.

[6]  M. Miravitlles,et al.  Costes de la EPOC en España. Estimación a partir de un estudio epidemiológico poblacional , 2004 .

[7]  M. Miravitlles,et al.  [Costs of chronic obstructive pulmonary disease in Spain. Estimation from a population-based study]. , 2004, Archivos de bronconeumologia.

[8]  M. Miravitlles,et al.  Treatment and quality of life in patients with chronic obstructive pulmonary disease , 2002, Quality of Life Research.

[9]  R. Pauwels,et al.  Chronic obstructive pulmonary disease: molecular and cellularmechanisms , 2003, European Respiratory Journal.

[10]  J. Díez,et al.  Tratamiento farmacológico de la EPOC en dos niveles asistenciales. Grado de adecuación a las normativas recomendadas , 2003 .

[11]  J. Wedzicha,et al.  Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. , 2003, American journal of respiratory and critical care medicine.

[12]  Ramon Gisbert,et al.  Costs of chronic bronchitis and COPD: a 1-year follow-up study. , 2003, Chest.

[13]  P. Jones,et al.  Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations , 2003, European Respiratory Journal.

[14]  J. L. Izquierdo Alonso,et al.  [Drug treatment of chronic obstructive pulmonary disease on two levels of patient care: degree of compliance with recommended protocols]. , 2003, Archivos de bronconeumologia.

[15]  C. Roussos,et al.  Strenuous Resistive Breathing Induces Plasma Cytokines Role of Antioxidants and Monocytes the Source of Cytokine Production during Resistive Breath , 2022 .

[16]  T. Seemungal,et al.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease , 2002, Thorax.

[17]  Jordi Alonso,et al.  Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.

[18]  M. Álvarez-Mon,et al.  AM3 (Inmunoferón) as an adjuvant to hepatitis B vaccination in hemodialysis patients. , 2002, Kidney international.

[19]  J. P. Pivel,et al.  Inmunoferon, a glycoconjugate of natural origin, regulates the liver response to inflammation and inhibits TNF-alpha production by an HPA axis-dependent mechanism. , 2002, International immunopharmacology.

[20]  J. P. Pivel,et al.  Modulation of inducible nitric oxide synthase (ONSI) expression by inmunoferon in an endotoxemic model in rats , 2002 .

[21]  P. Jones.  Interpreting thresholds for a clinically significant change in health status in asthma and COPD , 2002, European Respiratory Journal.

[22]  J. Izquierdo,et al.  Defective natural killer and phagocytic activities in chronic obstructive pulmonary disease are restored by glycophosphopeptical (inmunoferón). , 2001, American journal of respiratory and critical care medicine.

[23]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[24]  P M Calverley,et al.  Health status deterioration in patients with chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[25]  P. Barnes,et al.  Chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[26]  R. Stockley,et al.  Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. , 2000, The American journal of medicine.

[27]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[28]  M. Decramer,et al.  Skeletal muscle dysfunction in chronic obstructive pulmonary disease and chronic heart failure: underlying mechanisms and therapy perspectives. , 2000, The American journal of clinical nutrition.

[29]  A. Torres,et al.  Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. , 1999, The European respiratory journal.

[30]  W. Maziak,et al.  Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[31]  T. Seemungal,et al.  Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[32]  M. Ferrer,et al.  Chronic Obstructive Pulmonary Disease Stage and Health-Related Quality of Life , 1997, Annals of Internal Medicine.

[33]  P. Jones,et al.  Quality of life changes in COPD patients treated with salmeterol. , 1997, American journal of respiratory and critical care medicine.

[34]  J. Alonso,et al.  Chronic obstructive pulmonary disease stage and health-related quality of life. The Quality of Life of Chronic Obstructive Pulmonary Disease Study Group. , 1997, Annals of internal medicine.

[35]  E Monsó,et al.  Validity and reliability of the St George's Respiratory Questionnaire after adaptation to a different language and culture: the Spanish example. , 1996, The European respiratory journal.

[36]  M. Chirigos,et al.  AM3, an adjuvant to hepatitis B revaccination in non-responder healthy persons. , 1995, Journal of hepatology.